Company Description
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies.
In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services.
Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services.
The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
| Country | United States |
| Founded | 1904 |
| IPO Date | May 17, 2019 |
| Industry | Specialty Chemicals |
| Sector | Materials |
| Employees | 7,570 |
| CEO | Michael Stubblefield |
Contact Details
Address: Radnor Corporate Center, Building One, Suite 200, 100 Matsonford Road Radnor, Pennsylvania 19087 United States | |
| Phone | (610) 386-1700 |
| Website | avantorsciences.com |
Stock Details
| Ticker Symbol | AVTR |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001722482 |
| CUSIP Number | 05352A100 |
| ISIN Number | US05352A1007 |
| Employer ID | 82-2758923 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Michael Stubblefield | President, Chief Executive Officer and Director |
| R. Brent Jones | Executive Vice President and Chief Financial Officer |
| James Bramwell | Executive Vice President of Sales and Customer Excellence |
| Randy Lee Stone | Executive Vice President of Laboratory Solutions |
| Steven W. Eck | Senior Vice President, Corporate Controller and Chief Accounting Officer |
| Michael Wondrasch | Executive Vice President and Chief Information Officer |
| Tommy J. Thomas CPA | Vice President of Investor Relations |
| Claudius O. Sokenu | Executive Vice President, Corporate Secretary and Chief Legal and Compliance Officer |
| Allison K. Hosak | Senior Vice President of Global Communications and Brand |
| Kitty Sahin | Executive Vice President of Strategy and Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | 8-K | Current Report |
| Mar 29, 2024 | ARS | Filing |
| Mar 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 29, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 12, 2024 | 144 | Filing |
| Mar 1, 2024 | 144 | Filing |
| Feb 29, 2024 | 144 | Filing |
| Feb 29, 2024 | 144 | Filing |
| Feb 28, 2024 | 8-K | Current Report |